{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-117571","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.938220+00:00","generated_at":"2026-05-16T15:26:26.254301+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA grants Fast Track designation to Incannex's IHL-42X for obstructive sleep apnea","bullets":["FDA Fast Track designation for Incannex's IHL-42X for obstructive sleep apnea (OSA).","Phase 2 RePOSA study showed up to 83% reduction in AHI; safety and patient-reported outcomes positive.","Fast Track enables rolling NDA submission, more FDA interaction, and potential Accelerated Approval.","Incannex expects to receive FDA feedback on Phase 2 data and map path to late-stage development."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-117571","json":"https://secwatch.observer/filing/0001213900-25-117571.json","markdown":"https://secwatch.observer/filing/0001213900-25-117571.md","text":"https://secwatch.observer/filing/0001213900-25-117571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025117571/0001213900-25-117571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025117571/ea0268145-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:26:26.254301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}